Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 85 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)CompletedNCT02240433Phase 1
• HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)Status unknownNCT02239952Not applicable
• Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesStatus unknownNCT02238509Phase 2
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationStatus unknownNCT02233049Phase 2
• Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
• Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy ParticipantsCompletedNCT02231489Phase 1
• Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedNCT02230553Phase 1/2
• A Study of DCC-2701 in Participants With Advanced Solid TumorsTerminatedNCT02228811Phase 1
• Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedNCT02228369Phase 1
• An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
• Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerCompletedNCT02225405Phase 1
• Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
• Phase 1/1b Study of MGCD516 in Patients With Advanced CancerCompletedNCT02219711Phase 1
• Pharmacokinetic Study of JNJ-42756493 in Healthy ParticipantsCompletedNCT02218073Phase 1
• Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing TherapyStatus unknownNCT02216916Phase 2
• Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction ChemotherapyCompletedNCT02216617Phase 1
• Ph II CABOGIST in GISTCompletedNCT02216578Phase 2
• Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02215629Phase 1
• Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
• Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT02207504Phase 1
• A Phase 0 Study of AZD1775 in Recurrent GBM PatientsCompletedNCT02207010Early Phase 1
• Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
• KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach CancerWithdrawnNCT02205463Phase 1
• Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
• The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedNCT02204644Phase 3
• Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 2
• Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaActive, not recruitingNCT02203526Phase 1
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02201992Phase 3
• Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
• A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersCompletedNCT02199392Phase 1
• A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsCompletedNCT02199379Phase 1
• Regorafenib + Panitumumab for Colorectal CancersTerminatedNCT02199223Phase 1
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
• An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT02192697Phase 1/2
• Absolute Bioavailability Of BosutinibCompletedNCT02192294Phase 1
• Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2
• Deciphering Afatinib Response and Resistance With INtratumour HeterogeneityCompletedNCT02183883Phase 2
• EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung CancerCompletedNCT02183870Phase 2
• Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy SubjectsCompletedNCT02182258Phase 1
• A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedNCT02182232Phase 1
• Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT02182219Phase 1
• An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursCompletedNCT02182206Phase 1
• Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male VolunteersCompletedNCT02182193Phase 1
• Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male VolunteersCompletedNCT02182154Phase 1
• An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02182141Phase 1
• A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursCompletedNCT02182128Phase 1
• Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCompletedNCT02182102Phase 1
• Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male VolunteersCompletedNCT02182076Phase 1
• A Study With BIBF 1120 in Patients With Hormone Refractory Prostate CancerCompletedNCT02182063Phase 2
• Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung CancerCompletedNCT02182050Phase 2
• Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02181660Phase 1
• A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRTerminatedNCT02178397Phase 3
• Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasTerminatedNCT02177825Phase 2
• Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabTerminatedNCT02175654Phase 2
• Isoflavone Treatment for Postmenopausal Osteopenia.CompletedNCT02174666Not applicable
• An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two YearsTerminatedNCT02174445Phase 3
• Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male VolunteersCompletedNCT02171767Phase 1
• Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
• Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171728Phase 1
• BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male VolunteersCompletedNCT02171715Phase 1
• Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumoursCompletedNCT02171702Phase 1
• Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male VolunteersCompletedNCT02171689Phase 1
• BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
• Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171663Phase 1
• BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171650Phase 1
• Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171637Phase 1
• Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT02169180Phase 2
• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid TumorsCompletedNCT02164838Phase 1
• JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
• AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy SubjectsCompletedNCT02163161Phase 1
• Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsCompletedNCT02162355Phase 1
• Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT02161770Phase 1
• Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
• Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1
• Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic CancerCompletedNCT02154737Phase 1
• Photodynamic Therapy (PDT) for Oral DisinfectionCompletedNCT02152475Phase 1
• A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based ChemotherapyWithdrawnNCT02152059Phase 2
• Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung CancerStatus unknownNCT02151721Phase 1
• INCB047986 in Rheumatoid ArthritisTerminatedNCT02151474Phase 2
• Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedNCT02150733Phase 1
• Combination of Chemotherapy and Gefitinib as First-line TreatmentCompletedNCT02148380Not applicable
• A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02146118Phase 2
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsCompletedNCT02141425Phase 1
• Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCStatus unknownNCT02140333Phase 3
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02133157Phase 1
• Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02131584Phase 2
• A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerTerminatedNCT02131506Phase 1
• Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1WithdrawnNCT02129322Phase 2
• Explore the Synergy of Combination TKI TherapyWithdrawnNCT02129166Phase 1
• Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaStatus unknownNCT02125240Phase 3
• A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat CancerCompletedNCT02122913Phase 1
• Second Line Sorafenib After Pazopanib in Patients With RCCTerminatedNCT02122003Phase 2
• SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
• Safety Study of Regorafenib With PF-03446962 to Treat Colorectal CancerCompletedNCT02116894Phase 1
• The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)CompletedNCT02116712Phase 1
• Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsCompletedNCT02114658Phase 2

← Tyrosine Kinase Inhibitors overview